Fundraise completed
Renalytix (LSE:RENX) confirmed on 28 September 2026 that shareholders had approved the remaining parts of its Capital raise, allowing the final Tranche of new shares to be admitted to AIM the following day. This article explains how the kidney disease diagnostics company completed the fundraise, what the money is intended for, and the changes taking place on its board.
The business
Renalytix describes itself as a "precision medicine diagnostics company focussed on kidney disease". Its main product is kidneyintelX.dkd, a test intended to help clinicians assess and manage kidney disease. The company has entered a multi-year Partnership with Quest Diagnostics, a US laboratory services provider, under which collaboration on testing services is due to begin in 2027. James McCullough is chief executive, and the company's ordinary shares trade on AIM under the code RENX.
How the fundraise came together
According to the result of fundraise announcement on 3 September 2026, Renalytix raised £10.1 million gross through a placing and subscription at 6 pence per share. Separately, Heights Capital Management received conversion shares worth £3.5 million, giving a total transaction value of £13.6 million. A retail offer ran alongside. The first tranche of placing shares was expected to be admitted on 8 September, with the second tranche, the subscription shares and the retail offer shares dependent on a general meeting.
At that meeting, held on 28 September 2026, both resolutions passed, with about 99.86% and 99.77% of votes cast in favour. The company said 7,500,000 second-tranche placing shares, 52,792,950 subscription shares and 6,335,707 retail offer shares would be admitted on 29 September, after which it would have 670,459,333 ordinary shares in issue.
The company said the proceeds would help "pivot our operations to support national access and logistics with our new collaborator, Quest Diagnostics, for kidneyintelX.dkd testing services". At 6 pence each, the retail offer shares imply roughly £0.38 million, which broadly reconciles the £10.1 million placing and subscription with the £10.5 million gross proceeds cited in a later announcement.
Board changes and insider buying
On 28 September 2026, Renalytix also announced that non-executive chair Julian Baines will step down on 31 December 2026. He said that with the Quest partnership signed and "the successful fundraising, which provides £10.5 million in gross proceeds for the Company, I feel it is an appropriate time for me to stand down". He added: "I firmly believe that kidneyintelX.dkd will revolutionise the way clinicians manage kidney disease and deliver improved patient outcomes." The company said it was interviewing senior industry executives to support its US and global partnership and distribution strategy, with board nominations expected shortly.
Earlier, on 16 September 2026, the company reported that Mr McCullough had bought 500 American Depositary Shares, equivalent to 25,000 ordinary shares, taking his holding to 3,472,096 ordinary shares, about 0.58% of the issued capital. The purchases were made on 11 and 15 September at an average of US$4.30 per ADS. On 14 September, Renalytix also announced a change to its accounting reference date.
Risks and points to watch
The share count has grown substantially, so existing shareholders have been diluted. The Quest collaboration only begins in 2027, so commercial results from it are some way off, and the company must manage costs until Revenue builds. Further funding needs could bring more dilution. Adoption of a new diagnostic depends on clinicians, payers and reimbursement decisions. Leadership change at board level adds a period of transition while a new chair is found.
Conclusion
Renalytix completed its fundraise once shareholders approved the second tranche, subscription and retail offer, giving it about £10.5 million in gross proceeds to prepare kidneyintelX.dkd testing with Quest Diagnostics. Whether that funding is sufficient to reach meaningful revenue from the partnership is the key question ahead.
_11_18_2026_09_42_19_750506.jpg)
_11_18_2026_09_43_10_583784.jpg)




Please wait processing your request...